NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
about
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
NRAS mutations in cutaneous T ...... ltikinase inhibitor Sorafenib.
@en
type
label
NRAS mutations in cutaneous T ...... ltikinase inhibitor Sorafenib.
@en
prefLabel
NRAS mutations in cutaneous T ...... ltikinase inhibitor Sorafenib.
@en
P2093
P2860
P356
P1433
P1476
NRAS mutations in cutaneous T ...... ltikinase inhibitor Sorafenib.
@en
P2093
Claus-Detlev Klemke
Dorothee Süss
Jan P Nicolay
Karsten Gülow
Michael K Kießling
Peter H Krammer
Tabea Schlör
P2860
P304
45687-45697
P356
10.18632/ONCOTARGET.17669
P407
P577
2017-05-07T00:00:00Z